[SCHEDULE 13G/A] Savara Inc. SEC Filing

Rhea-AI Filing Summary

Frazier-affiliated investment vehicles disclosed shared voting and dispositive power over specified Savara Inc. (SVRA) common stock positions. Frazier Life Sciences Public Fund, L.P. directly holds 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P. holds 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P. holds 324,346 shares (0.2%); and Frazier Life Sciences XI, L.P. holds 1,503,190 shares (0.9%). These percentages are calculated using 172,836,922 shares outstanding as reported by the issuer. The filing clarifies that certain investment committees act by majority vote and explicitly corrects prior attributions of beneficial ownership to individual committee members.

Positive

• Disclosure of exact share counts and percentages for multiple Frazier-affiliated funds (e.g., 6,745,296 shares = 3.9%)
• Correction of prior attributions clarifies that investment committee members are not individually attributed beneficial ownership, improving reporting accuracy

Negative

• No sole voting power reported for any reporting person (all listed sole voting power values are 0.00)
• No single reporting person exceeds 5% in the issuer's outstanding common stock as reported on the cover pages (percentages: 3.9%, 1.7%, 0.9%, 0.2%)

Insights

Financial Analyst

TL;DR: Passive, disclosed stakes across several Frazier funds; corrections to prior attributions improve transparency without signaling control.

The filing reports specific share counts and percentages for multiple Frazier-affiliated funds, with the largest single reported holding being 6,745,296 shares (3.9%) by Frazier Life Sciences Public Fund, L.P. The statement emphasizes shared voting/dispositive power and clarifies that investment committees govern certain vehicles by majority vote, removing earlier attributions to individual committee members. From a market perspective, these disclosures document ownership and correct prior reporting but do not, by themselves, indicate a change in corporate control.

Corporate Governance Expert

TL;DR: The amendment corrects beneficial ownership attributions and clarifies governance of underlying funds, enhancing disclosure accuracy.

The filing explicitly corrects earlier attributions of beneficial ownership to individual members of certain investment committees, stating those committees act by majority vote and therefore committee members are not attributed the securities. This clarification reduces potential misstatements about who exercises voting or dispositive power. The filing also shows that reported holdings are structured through multiple affiliated entities and that no reporting person claims sole voting or sole dispositive power over the shares disclosed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Savara Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

805111101

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,745,296.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,745,296.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,745,296.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,745,296.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,745,296.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,745,296.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,745,296.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,745,296.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,745,296.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Frazier Life Sciences Public Overage Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,889,469.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,889,469.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,889,469.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLSP Overage, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,889,469.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,889,469.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,889,469.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLSP Overage, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,889,469.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,889,469.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,889,469.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Frazier Life Sciences X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 324,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 324,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

324,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLS X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 324,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 324,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

324,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLS X, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 324,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 324,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

324,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,503,190.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,503,190.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,503,190.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,503,190.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,503,190.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,503,190.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,503,190.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,503,190.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,503,190.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

James N. Topper

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 324,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 324,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

324,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 324,346 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Patrick J. Heron

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 324,346.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 324,346.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

324,346.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 324,346 shares of Common Stock held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 172,836,922 shares of Common Stock outstanding on May 13, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Albert Cha

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

James Brush

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 805111101

1

Names of Reporting Persons

Daniel Estes

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Savara Inc.
(b)	Address of issuer's principal executive offices: 1717 Langhorne Newtown Road, Suite 300, Langhorne, PA, 19047.
Item 2.
(a)	Name of person filing: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF") FHMLSP Overage, L.P. FHMLSP Overage, L.L.C. Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron") Albert Cha ("Cha") James Brush ("Brush") Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
(b)	Address or principal business office or, if none, residence: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite B Palo Alto, CA 94304
(c)	Citizenship: The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 805111101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 6,745,296 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLSPOF directly holds 2,889,469 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. FLS X directly holds 324,346 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. FLS XI directly holds 1,503,190 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements. Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)	Percent of class: The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	08/14/2025

FHMLSP, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	08/14/2025

FHMLSP, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:	08/14/2025

Frazier Life Sciences Public Overage Fund, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:	08/14/2025

FHMLSP Overage, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:	08/14/2025

FHMLSP Overage, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:	08/14/2025

Frazier Life Sciences X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:	08/14/2025

FHMLS X, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:	08/14/2025

FHMLS X, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:	08/14/2025

Frazier Life Sciences XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	08/14/2025

FHMLS XI, L.P.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	08/14/2025

FHMLS XI, L.L.C.

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:	08/14/2025

James N. Topper

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/14/2025

Patrick J. Heron

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:	08/14/2025

Albert Cha

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/14/2025

James Brush

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:	08/14/2025

Daniel Estes

Signature:	/s/ Steve R. Bailey
Name/Title:	By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:	08/14/2025

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of May 15, 2025, incorporated by reference into this Statement.

FAQ

What holdings did Frazier report in Savara (SVRA)?

Frazier Life Sciences Public Fund, L.P.: 6,745,296 shares (3.9%); Frazier Life Sciences Public Overage Fund, L.P.: 2,889,469 shares (1.7%); Frazier Life Sciences X, L.P.: 324,346 shares (0.2%); Frazier Life Sciences XI, L.P.: 1,503,190 shares (0.9%).

On what basis were the percentages calculated in the filing?

Percentages are calculated using 172,836,922 shares outstanding as reported by the issuer in its Quarterly Report referenced in the filing.

Does any reporting person claim sole voting or dispositive power over SVRA shares?

No. The filing shows 0.00 sole voting power and 0.00 sole dispositive power for the reporting persons listed; reported power is shared where indicated.

Did the filing correct previous disclosures about beneficial ownership?

Yes. The statement expressly corrects prior attributions by indicating investment committees act by majority vote and individual committee members are not attributed the securities held by certain funds.

Who are the named reporting persons and representatives listed in the filing?

Reporting persons include multiple Frazier entities (e.g., Frazier Life Sciences Public Fund, L.P.; Frazier Life Sciences X, L.P.; Frazier Life Sciences XI, L.P.) and individuals identified as members: James N. Topper, Patrick J. Heron, Albert Cha, James Brush, and Daniel Estes.

Where is Savara's principal executive office listed in the filing?

The filing lists Savara Inc.'s principal executive offices at 1717 Langhorne Newtown Road, Suite 300, Langhorne, PA 19047.